Clinical Trial Update: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for ADCT-301 (camidanlumab tesirine) in selected advanced solid tumors; the study has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ADCT-301 (camidanlumab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2024-06-13